Neurocrine Biosciences Inc. (NBIX)
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Neurocrine (NBIX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive?
Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neurocrine Biosciences, Inc. (NBIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neurocrine's movement disorder treatment fails late-stage trial
Neurocrine Biosciences said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts the brain's ability to control muscles.
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neurocrine Biosciences, Inc. ( NBIX ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Kyle Gano - CEO & Director Eric Benevich - Chief Commercial Officer Sanjay Keswani - Chief Medical Officer Conference Call Participants Phoebe Tan - Jefferies LLC, Research Division Presentation Phoebe Tan Jefferies LLC, Research Division Hi, everyone. My name is Phoebe Tan, and I am an Associate on Akash Tewari's team.
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain?
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes Neurocrine (NBIX) a New Strong Buy Stock
Neurocrine (NBIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Todd Tushla Kyle Gano - CEO & Director Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Sanjay Keswani - Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division David Amsellem - Piper Sandler & Co., Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Brian Abrahams - RBC Capital Markets, Research Division Marc Goodman - Leerink Partners LLC, Research Division Sean Laaman - Morgan Stanley, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Ashwani Verma - UBS Investment Bank, Research Division Ami Fadia - Needham & Company, LLC, Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Myles Minter - William Blair & Company L.L.C.
